Squamous cell carcinoma - Plateepitelkarsinom
☆ I 2022 Stiftung Warentest-resultatene fra Tyskland var forbrukertilfredsheten med ModelDerm bare litt lavere enn med betalte telemedisinkonsultasjoner.
Squamous cell carcinoma well differentiated ― En tilstøtende aktinisk keratose er observert.
References
Squamous cell carcinoma (SCC) er den nest vanligste hudkreften i USA, etter basal cell carcinoma. Det starter vanligvis fra precancerøse lesjoner kalt actinic keratosis , og kan spre seg til andre deler av kroppen. Hovedårsaken er eksponering for ultrafiolett (UV) stråling fra solen, som akkumuleres over tid. Behandling innebærer vanligvis kirurgisk fjerning, spesielt for SCC på hode og nakke. Strålebehandling er et alternativ for eldre pasienter eller de som ikke kan opereres. Immunsuppresjon øker risikoen for SCC. Selv om det er sjeldent, kan SCC spre seg, spesielt hos pasienter med svekket immunforsvar. Regelmessige kontroller og solbeskyttelse er viktig for de med SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) er den nest vanligste kreften hos mennesker, og antallet øker. Selv om CSCC vanligvis viser en godartet klinisk atferd, kan den spre seg både lokalt og til andre deler av kroppen. Forskere har identifisert spesifikke veier involvert i CSCC-utvikling, som fører til nye behandlinger. Det høye antallet mutasjoner og økt risiko hos immunsupprimerte pasienter har ført til utviklingen av immunterapi. Denne anmeldelsen ser på de genetiske røttene til CSCC og de nyeste behandlingene rettet mot spesifikke molekyler og immunsystemet.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnose og behandling
#Dermoscopy
#Skin biopsy